News

Twinning – Number of submitted proposals

Published on
| 3 years ago
Programmes
  • Widening/Spreading

The Calls HORIZON-WIDERA-2023-ACCESS-02-01 Twinning Bottom Up and HORIZON-WIDERA-2023-ACCESS-02-02 Twinning Green Deal have closed on 28/10/2023.

848 proposals have been submitted.

The breakdown per call topic is:

Twinning Bottom Up: 675 proposals

Twinning Green Deal: 173 proposals

Evaluation results are expected to be communicated in February 2024.

Source: Funding and Tenders Portal

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2070 articles available Browse all news
  • Defence
  • NATO-EDA

NATO Engine pilot opens second RFI

The NATO Support and Procurement Agency has launched a second request for information for the NATO Engine pilot. The call targets start-ups, SMEs and scale-ups looking for production capacity for defence or dual-use projects. Registration opened on 17 November 2026 and closes on 31 December 2026.

Read more
  • ERC
  • MSCA
  • Research Infrastructures
  • EIC

Innonext the Next Generation Innovation Talent’s Initiative call open

InnoNext is a two-year project funded under the European Innovation Council (EIC) that was extended by one year until 31 July 2027. The objective of the project is to match visiting researchers with start-ups or SMEs which host the visiting researchers during an internship. The researchers and companies involved are funded by an EU funding...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.